Triple

T363284
Position Surface form Disambiguated ID Type / Status
Subject Genentech E7901 entity
Predicate notableProduct P1448 FINISHED
Object Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
 E46089 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Rituxan | Statement: [Genentech, notableProduct, Rituxan]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: Rituxan
Context triple: [Genentech, notableProduct, Rituxan]
  • A. Tysabri
    Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
  • B. Tecfidera
    Tecfidera is an oral disease-modifying medication used to treat relapsing forms of multiple sclerosis by reducing inflammation and relapse frequency.
  • C. Vumerity
    Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
  • D. Aduhelm
    Aduhelm is an Alzheimer’s disease drug developed by Biogen that targets amyloid-beta plaques in the brain.
  • E. Plegridy
    Plegridy is a pegylated interferon beta-1a medication used to treat relapsing forms of multiple sclerosis.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Rituxan
Triple: [Genentech, notableProduct, Rituxan]
Generated description
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: Rituxan
Target entity description: Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
  • A. Tysabri
    Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.
  • B. Tecfidera
    Tecfidera is an oral disease-modifying medication used to treat relapsing forms of multiple sclerosis by reducing inflammation and relapse frequency.
  • C. Vumerity
    Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
  • D. Aduhelm
    Aduhelm is an Alzheimer’s disease drug developed by Biogen that targets amyloid-beta plaques in the brain.
  • E. Plegridy
    Plegridy is a pegylated interferon beta-1a medication used to treat relapsing forms of multiple sclerosis.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69a2e7e880008190a6ad7e06e5d03007 completed Feb. 28, 2026, 1:04 p.m.
NER Named-entity recognition batch_69a2ebd1016481909b8ba3b047a47145 completed Feb. 28, 2026, 1:21 p.m.
NED1 Entity disambiguation (via context triple) batch_69a3e86533a481909bab5f0b52114c6a completed March 1, 2026, 7:19 a.m.
NEDg Description generation batch_69a3e99fd210819099e83cd183a4daa7 completed March 1, 2026, 7:24 a.m.
NED2 Entity disambiguation (via description) batch_69a3ea45c86c8190a6c215430601ad15 completed March 1, 2026, 7:27 a.m.
Created at: Feb. 28, 2026, 1:08 p.m.